How Many Days Can You Go Between Allergy Shots? Missed-Dose Protocols Explained

What happens when you miss one shot during build-up depends on how many days have passed. A gap of less than 2 weeks (14 days) is generally tolerated without a dose reduction if you have no history of prior systemic reactions — your dose is typically advanced as planned. A gap of 2-3 weeks usually means repeating your last dose rather than advancing to the next level. A gap of 3-4 weeks typically requires stepping back one concentration. A gap of 4-5 weeks usually requires stepping back two concentrations. In all cases, confirm the appropriate adjustment with your allergist before your next dose — the exact protocol varies slightly by practice and by your personal reaction history. With an at-home program such as Curex your care team is reachable by message to set this adjustment, and dose changes are supervised live over Zoom; do not assume you can resume at your previous dose after a gap of more than one week without checking with your provider.

Maintenance phase has more scheduling flexibility than build-up, but gaps still require careful management. A gap of up to 5 weeks from your last maintenance injection is typically acceptable — your allergist will likely continue at full maintenance dose. A gap of 5-7 weeks usually prompts a 25% dose reduction. A gap of 7-11 weeks may require reducing by approximately 45%. A gap of 8-15 weeks often means reducing by about 55% and working back up over a few visits. The most serious situation is a gap of 13-16 weeks or longer — at that point, many allergists recommend restarting the entire build-up phase from the beginning, because the immune tolerance built during prior treatment may have partially reversed. Always contact your allergist before resuming after any gap longer than your standard maintenance interval.

A few days of flexibility is usually built into the schedule. During build-up, most protocols allow shifting an appointment by 2-4 days without a dose adjustment, as long as this doesn't push the gap past the 14-day threshold. During maintenance, the standard 2-4 week interval has inherent flexibility — going from a 4-week to a 5-week interval is within normal parameters. However, it's always prudent to inform your allergist's office of significant scheduling changes, especially during the build-up phase when dose escalation decisions are made at every visit. If you're unsure whether your gap is within the acceptable window, a quick call to the nurse line is faster than guessing and safer than experiencing an unexpected dose-related reaction.

Real-world data suggest that schedule non-adherence is one of the most common reasons allergy shots fail to deliver expected results. A landmark Dutch database study (Kiel et al., JACI 2013) found that only 23% of allergy shot patients completed the minimum recommended 3-year course, with most dropout occurring in the first 1-2 years. Each time a dose stepback is required — because of a gap — the build-up phase effectively extends, delaying the time to reaching maintenance and the time to experiencing clinical benefit. Patients who maintain greater than 85% appointment adherence during build-up typically reach the maintenance phase 4-6 weeks faster than those with frequent gaps, according to retrospective practice estimates. Beyond scheduling delays, insufficient cumulative allergen exposure — the direct consequence of repeated gaps and dose reductions — may reduce the magnitude of long-term immune tolerance achieved.

A gap of 6 months or longer is a significant disruption requiring a careful conversation with your allergist. During maintenance, most practice guidelines recommend restarting from the very beginning — the full build-up sequence — after a gap of 3-4 months or more, because the immune tolerance accumulated during prior treatment is considered to have substantially waned. The AAAAI Practice Parameter (Cox et al., JACI 2011) suggests that a gap exceeding 90 days during build-up requires restarting from the first vial. After 6 months during maintenance, the same logic applies with additional caution, particularly if you had any prior systemic reactions. Your allergist will evaluate your prior reaction history and current immunologic status before making a restart recommendation. In some cases, a restart from an intermediate point rather than the absolute beginning may be clinically justified.

Rush and cluster immunotherapy protocols have their own dose-adjustment guidelines that differ somewhat from conventional build-up schedules. With rush protocols — which compress the build-up into 1-3 days — patients typically reach maintenance much faster, so missed doses after completion fall under the standard maintenance gap rules described above. Cluster immunotherapy, which reaches maintenance in 4-8 weeks with multiple injections per visit, uses interval-based adjustment similar to conventional build-up once the escalation phase is complete. Both accelerated protocols have slightly higher per-injection systemic reaction rates than conventional schedules, so dose adjustments for gaps are applied conservatively. Your allergist's office will have specific written protocols for your immunotherapy type — always ask for a copy of the dose-adjustment table so you know exactly what to expect if scheduling disruptions occur.

Consistent scheduling strategies make a significant difference in completion rates. Designating a fixed appointment day and time each week during build-up — treating it like a medical appointment that cannot be moved except in genuine emergencies — is the single most effective approach. Many allergy offices offer walk-in shot hours during specific time blocks, removing the need to schedule each visit individually, which can reduce the friction of rescheduling. Setting calendar reminders two days before each appointment gives enough lead time to rearrange conflicts without missing the visit entirely. For patients whose work or travel schedules make consistent weekly visits genuinely impossible, discussing a cluster immunotherapy protocol with your allergist — which reaches maintenance in 4-8 weeks rather than 8-28 — can substantially shorten the high-frequency phase of treatment. Vaswani et al. (Ann Allergy Asthma Immunol 2015) found that inconvenience and travel burden were the second most common reason patients discontinued SCIT after cost.